Document is current
Any future updates will be listed below
-
Authors
Clausen, Clara Lundetoft https://orcid.org/0000-0002-1745-2623
Bryrup, Thomas
Hansen, Christian Leo
Faurholt-Jepsen, Daniel
Meddis, Alessandra
Almdal, Thomas Peter
Snorgaard, Ole
Jørgensen, Henrik Løvendahl
Helleberg, Marie
Smitt, Margit
Warmberg, Christian Aage
Tjelle, Klaus
Ulrik, Charlotte Suppli
Andreasen, Anne Sofie
Bestle, Morten
Poulsen, Lone
Marcussen, Klaus Vennick
Wiese, Lothar
Munch, Marie Warrer
Perner, Anders
Krogh-Madsen, Rikke
Benfield, Thomas
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Received: 12 November 2024
Accepted: 29 June 2025
First Online: 15 July 2025
Declarations
:
: The COVID STEROID 2 trial was approved by the Scientific Ethics Committee of the Capital Region of Denmark (H-20051056) and registered at ClinicalTrials.gov (NCT04509973) and ctri.nic.in (CTRI/2020/10/028731) on August 11th, 2020. The secondary analysis was approved according to Danish Healthcare Law § 46, Sect. 2 by the Capital Region (R-24013197).
: Not applicable.
: T.B. reports grants from Novo Nordisk Foundation, Lundbeck Foundation, Simonsen Foundation, GSK, and Pfizer; personal fees from GSK, Pfizer, Bavarian Nordic, Gilead, MSD, Janssen, Moderna and Astra Zeneca; outside the submitted work. TPA holds stocks in Novo Nordisk A/S; outside the submitted work. No other disclosures were reported.
